OverviewSuggest Edit

BioCryst is a pharmaceutical company that designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and inflammatory diseases. BioCryst uses state-of-the-art structure-guided drug design, which incorporates multiple scientific disciplines including biology, crystallography, medicinal chemistry and computer modeling, in order to most efficiently develop new therapeutic candidates. 
BioCryst's core development programs include BCX7353 and additional 2nd generation oral inhibitors of plasma kallikrein for hereditary angioedema; and BCX4430 (GALIDESIVIR), a broad spectrum antiviral for hemorrhagic fevers.

TypePublic
Founded1986
HQDurham, US
Websitebiocryst.com

Latest Updates

Employees (est.) (Jan 2020)140(+40%)
Job Openings7
Revenue (FY, 2019)$48.8 M(+137%)
Share Price (Oct 2020)$3.7 (+3%)
Cybersecurity ratingAMore

Key People/Management at BioCryst Pharmaceuticals

Robert A. Ingram

Robert A. Ingram

Chairman of the Board
Stephanie Angelini

Stephanie Angelini

Senior Vice President, Human Resources
Alane Barnes

Alane Barnes

Senior Vice President, Chief Legal Officer
Yarlagadda S. Babu

Yarlagadda S. Babu

Senior Vice President, Drug Discovery
Elliott Berger

Elliott Berger

Senior Vice President, Regulatory Affairs
Anthony Doyle

Anthony Doyle

Senior Vice President, Chief Financial Officer
Show more

BioCryst Pharmaceuticals Office Locations

BioCryst Pharmaceuticals has offices in Durham and Hoover
Durham, US (HQ)
4505 Emperor Blvd #200
Hoover, US
2100 Riverchase Center #200
Show all (2)

BioCryst Pharmaceuticals Financials and Metrics

BioCryst Pharmaceuticals Revenue

BioCryst Pharmaceuticals's revenue was reported to be $48.84 m in FY, 2019
USD

Revenue (Q2, 2020)

2.9m

Gross profit (Q2, 2020)

2.9m

Gross profit margin (Q2, 2020), %

100%

Net income (Q2, 2020)

(38.6m)

EBIT (Q2, 2020)

(38.5m)

Market capitalization (29-Oct-2020)

658.6m

Closing stock price (29-Oct-2020)

3.7

Cash (30-Jun-2020)

173.5m

EV

587.3m
BioCryst Pharmaceuticals's current market capitalization is $658.6 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

19.6m26.3m17.3m13.6m48.3m26.4m25.2m20.7m48.8m

Cost of goods sold

1.0k1.4m2.3m1.1m3.7m

Gross profit

13.6m46.9m24.1m24.0m45.1m

Gross profit Margin, %

100%97%91%95%92%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

3.7m5.2m12.2m4.2m5.8m3.6m2.4m3.5m1.5m3.2m6.8m25.8m11.0m4.8m4.8m7.8m9.4m3.1m8.8m4.0m12.5m1.5m5.9m1.4m1.8m4.8m2.9m

Cost of goods sold

15.0k1.3m1.1m1.4m

Gross profit

6.8m9.6m7.6m4.5m2.9m

Gross profit Margin, %

100%88%87%76%100%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

16.4m20.9m21.2m54.5m28.9m22.1m50.3m26.7m114.2m

Accounts Receivable

5.8m4.6m2.1m6.2m6.1m4.3m22.1m

Prepaid Expenses

378.0k1.1m1.7m6.2m4.9m1.4m2.4m4.4m

Inventories

263.0k4.0m683.0k1.6m500.0k1.6m
USDQ2, 2011

Debt/Equity

0.8 x

Debt/Assets

0.3 x

Financial Leverage

2.8 x
Show all financial metrics

BioCryst Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

BioCryst Pharmaceuticals Online and Social Media Presence

Embed Graph

BioCryst Pharmaceuticals News and Updates

Thinking about buying stock in Sorrento Therapeutics, FAT Brands, BioCryst Pharmaceuticals, TOP Ships, or Tesla?

NEW YORK, Aug. 13, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, FAT, BCRX, TOPS, and TSLA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Global Hereditary Angioedema Therapeutics Market 2018-2022: Market to Grow at a CAGR of 8.94% with BioCryst Pharmaceuticals, Cipla, CSL, Pharming Group & Shire Dominating

DUBLIN, Sept. 25, 2018 /PRNewswire/ -- The "Global Hereditary Angioedema Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Hereditary Angioedema Therapeutics Market to grow at a CAGR of 8.94% during the period 2018-2022. The report...

Hereditary Angioedema Drug Market insightful analysis of current Scenario and future Growth Prospect including key players: Shire plc, CSL Limited, IBio, BioCryst Pharmaceuticals

A new business intelligence report released by HTF MI with title “Global Hereditary Angioedema Drug Sales Market Report 2018” that targets and provides comprehensive market analysis with future prospects to 2023. Posted via Industry Today. Follow us on Twitter @IndustryToday

BioCryst Pharmaceuticals Blogs

Galidesivir Stops Zika Viral Replication in Primate Model

— Data published in Science Translational Medicine — —Broad-spectrum antiviral activity against multiple RNA viruses — RESEARCH TRIANGLE PARK, N.C., June 10, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data published in Science Translational Medicine

BioCryst Announces Berotralstat Expanded Access Program for Patients with Hereditary Angioedema in United States

RESEARCH TRIANGLE PARK, N.C., June 09, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has established an expanded access program (EAP) with oral, once-daily berotralstat, an investigational drug, for patients with hereditary angioedema (HAE)

BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock and Pre-Funded Warrants

RESEARCH TRIANGLE PARK, N.C., June 01, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the completion of an underwritten public offering of 22,044,447 shares of its common stock, including 3,333,334 shares sold pursuant to the exercise in full of the

BioCryst to Present at Jefferies Virtual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10:30 a.m. ET. Links to a live audio webcast and replay of this

BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants

BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants Content Import Wed, 05/27/2020 - 16:01 BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants May 27, 2020 at 4:01 PM EDT This release is a backfill from a News Wire…

BioCryst to Present New Berotralstat Data at European Academy of Allergy and Clinical Immunology Digital Congress

BioCryst to Present New Berotralstat Data at European Academy of Allergy and Clinical Immunology Digital Congress Content Import Tue, 05/26/2020 - 07:00 BioCryst to Present New Berotralstat Data at European Academy of Allergy and Clinical Immunology Digital Congress May 26, …
Show more

BioCryst Pharmaceuticals Frequently Asked Questions

  • When was BioCryst Pharmaceuticals founded?

    BioCryst Pharmaceuticals was founded in 1986.

  • Who are BioCryst Pharmaceuticals key executives?

    BioCryst Pharmaceuticals's key executives are Robert A. Ingram, Stephanie Angelini and Alane Barnes.

  • How many employees does BioCryst Pharmaceuticals have?

    BioCryst Pharmaceuticals has 140 employees.

  • What is BioCryst Pharmaceuticals revenue?

    Latest BioCryst Pharmaceuticals annual revenue is $48.8 m.

  • What is BioCryst Pharmaceuticals revenue per employee?

    Latest BioCryst Pharmaceuticals revenue per employee is $348.8 k.

  • Who are BioCryst Pharmaceuticals competitors?

    Competitors of BioCryst Pharmaceuticals include IBL International, CANbridge Life Sciences and Galecto.

  • Where is BioCryst Pharmaceuticals headquarters?

    BioCryst Pharmaceuticals headquarters is located at 4505 Emperor Blvd #200, Durham.

  • Where are BioCryst Pharmaceuticals offices?

    BioCryst Pharmaceuticals has offices in Durham and Hoover.

  • How many offices does BioCryst Pharmaceuticals have?

    BioCryst Pharmaceuticals has 2 offices.